MedTrace Logo

eHealth-based Bavarian Alternative Detection of Atrial Fibrillation: A Randomized Controlled Trial (eBRAVE-AF)

NCT04250220 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4400

Last updated 2021-06-18

No results posted yet for this study

Summary

Atrial fibrillation (AF) is the most common arrhythmia in western countries and causes of up to one quarter of ischemic strokes. The randomized eHealth-based Bavarian Alternative Detection of Atrial Fibrillation study (eBRAVE-AF) tests the efficacy of an e-health based strategy for the detection of AF. The e-health-based strategy consists of a smartphone-based photophlethysmographic (PPG) screening and an ECG-based validation.

Conditions

Interventions

DIAGNOSTIC_TEST

e-Health based strategy: PPG-based screening using a smartphone and ECG patch

PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch

Sponsors & Collaborators

  • Preventicus GmbH

    collaborator INDUSTRY

  • Versicherungskammer Bayern

    collaborator UNKNOWN

  • LMU Klinikum

    lead OTHER

Principal Investigators

  • Axel Bauer, MD · LMU Klinikum

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2021-07-31
Completion
2021-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04250220 on ClinicalTrials.gov